SLRXSalarius Pharmaceuticals, Inc.

Nasdaq salariuspharma.com


$ 0.50 $ 0.00 (-0.78 %)    

Monday, 22-Apr-2024 12:25:05 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 0.4951
$ 0.50
$ 0.00 x 0
$ 0.00 x 0
$ 0.50 - $ 0.50
$ 0.43 - $ 2.31
4,071
na
1.62M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-22-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-27-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-05-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-25-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-18-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-23-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 07-17-2019 06-30-2019 10-Q
20 05-01-2019 03-31-2019 10-Q
21 03-06-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-02-2018 03-31-2018 10-Q
25 03-07-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 08-02-2017 06-30-2017 10-Q
28 05-03-2017 03-31-2017 10-Q
29 03-08-2017 12-31-2016 10-K
30 11-02-2016 09-30-2016 10-Q
31 08-03-2016 06-30-2016 10-Q
32 05-04-2016 03-31-2016 10-Q
33 03-08-2016 12-31-2015 10-K
34 11-04-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-06-2015 03-31-2015 10-Q
37 03-24-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

 why-salarius-pharmaceuticals-shares-are-trading-higher-by-around-31-here-are-20-stocks-moving-premarket

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter re...

 dada-nexus-salarius-pharmaceuticals-and-3-stocks-to-watch-heading-into-monday

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as foll...

 salarius-pharmaceuticals-q4-2023-gaap-eps-022-beats-101-estimate

Salarius Pharmaceuticals (NASDAQ:SLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate...

 salarius-provides-update-on-strategic-review-process-and-plans-to-support-ongoing-seclidemstat-clinical-trials-by-further-reducing-expenses-implementing-a-series-of-cost-savings-measures-designed-to-extend-expected-cash-runway-into-the-first-half-of-2025

Company implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first hal...

 why-datchat-shares-are-trading-lower-by-around-33-here-are-20-stocks-moving-premarket

Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offe...

 salarius-pharmaceuticals-issued-us-patent-no-11773080-titled-deuterium-enriched-isoindolinonyl-azepanediones-and-related-compounds-and-methods-of-treating-medical-disorders-using-same

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now i...

 investigator-initiated-phase-12-clinical-trial-using-salarius-pharmaceuticals-seclidemstat-in-combination-with-azacitidine-to-treat-hematologic-cancers-resumes-patient-enrollment

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at ...

 salarius-pharmaceuticals-13d-filing-shows-elvin-lee-reported-609-stake-in-co-as-of-23-october-2023

- SEC Filing

 stocks-that-hit-52-week-lows-on-friday

  During the Friday's sesion, 157 stocks hit new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION